Shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) traded down 0.1% on Tuesday . The company traded as low as $12.95 and last traded at $13.39. 178,928 shares traded hands during trading, a decline of 72% from the average session volume of 642,984 shares. The stock had previously closed at $13.37.
A number of analysts recently weighed in on the stock. Oppenheimer cut shares of Zynerba Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, August 14th. Zacks Investment Research cut shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price target on shares of Zynerba Pharmaceuticals in a research note on Tuesday, August 8th. Jefferies Group cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price target for the stock from $12.00 to $7.00 in a research note on Tuesday, August 15th. Finally, ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. Zynerba Pharmaceuticals presently has an average rating of “Hold” and an average target price of $15.00.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.05). During the same period in the prior year, the firm posted ($0.67) EPS. equities research analysts predict that Zynerba Pharmaceuticals, Inc. will post -2.49 EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors purchased a new position in shares of Zynerba Pharmaceuticals in the 2nd quarter valued at about $110,000. Zeke Capital Advisors LLC purchased a new position in shares of Zynerba Pharmaceuticals in the 3rd quarter valued at about $114,000. The Manufacturers Life Insurance Company purchased a new position in shares of Zynerba Pharmaceuticals in the 2nd quarter valued at about $158,000. Cowen Inc. purchased a new position in shares of Zynerba Pharmaceuticals in the 3rd quarter valued at about $167,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Zynerba Pharmaceuticals in the 2nd quarter valued at about $207,000. Institutional investors and hedge funds own 26.95% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/05/zynerba-pharmaceuticals-zyne-shares-down-0-1.html.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
What are top analysts saying about Zynerba Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zynerba Pharmaceuticals Inc. and related companies.